MedTrace Logo

Screened Health Assessment & Pacer Evaluation

NCT00312611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of the Transneuronix IGS System in a population of patients with a BMI between 35 and 55.

Conditions

Interventions

DEVICE

Transcend II Implantable Gastric Stimulator (IGS), Model 8848

Sponsors & Collaborators

Principal Investigators

  • David Sarwer, PhD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2006-08-31
Completion
2006-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312611 on ClinicalTrials.gov